Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
- Br. Med. J., May 28 2024, 385 | https://doi.org/10.1136/bmj-2023-078876